Bristol-Myers Squibb Co (BMY) : Nippon Life Global Investors Americas reduced its stake in Bristol-Myers Squibb Co by 4.12% during the most recent quarter end. The investment management company now holds a total of 284,060 shares of Bristol-Myers Squibb Co which is valued at $17,319,138 after selling 12,220 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Bristol-Myers Squibb Co makes up approximately 1.59% of Nippon Life Global Investors Americas’s portfolio.
Other Hedge Funds, Including , Secor Capital Advisors Lp reduced its stake in BMY by selling 3,714 shares or 25.48% in the most recent quarter. The Hedge Fund company now holds 10,862 shares of BMY which is valued at $662,256. Bristol-Myers Squibb Co makes up approx 0.09% of Secor Capital Advisors Lp’s portfolio.Bailard boosted its stake in BMY in the latest quarter, The investment management firm added 1,436 additional shares and now holds a total of 20,034 shares of Bristol-Myers Squibb Co which is valued at $1,221,473. Bristol-Myers Squibb Co makes up approx 0.14% of Bailard’s portfolio.Smith Salley Associates boosted its stake in BMY in the latest quarter, The investment management firm added 8,085 additional shares and now holds a total of 49,748 shares of Bristol-Myers Squibb Co which is valued at $3,721,648. Bristol-Myers Squibb Co makes up approx 0.84% of Smith Salley Associates’s portfolio.Parsec Financial Management reduced its stake in BMY by selling 800 shares or 10.49% in the most recent quarter. The Hedge Fund company now holds 6,827 shares of BMY which is valued at $510,728. Bristol-Myers Squibb Co makes up approx 0.05% of Parsec Financial Management’s portfolio.
Bristol-Myers Squibb Co closed down -1.11 points or -1.87% at $58.3 with 2,10,07,446 shares getting traded on Wednesday. Post opening the session at $59.5, the shares hit an intraday low of $58.07 and an intraday high of $59.52 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The company’s management has announced Oct 5, 2016 as the ex-dividend date and fixed the record date on Oct 7, 2016. The payable date has been fixed on Nov 1, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold” and Lowered the Price Target to $ 62 from a previous price target of $68 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.